Last update: Feb. 11, 2020
Minimal risk for breastfeeding and infant.
Approved as an antiemetic and prokinetic in many countries, although not in the US (Rowe 2013, Sachs 2013, Da Silva 2004) and often prescribed in young infants for the treatment of gastroesophageal reflux disease. Indicated for the control of nausea and vomiting.
Oral administration 3 times a day.
It is excreted in breastmilk in clinically insignificant amounts (Knoppert 2013, Wan 2008) and no problems have been recorded in infants whose mothers were taking it (Madjunkov 2017, Osadchy 2012, Da Silva 2001, De Leo 1986, Petraglia 1985).
Being a dopamine antagonist, it increases the production of prolactin (Hofmeyr 1985, Brouwers 1980) and of milk, being able to produce galactorrhea (Cann 1983), so it is widely used as a galactogogue (Brodribb 2018, Rowe 2013, Grzeskowiak 2013, Anderson 2013, Winterfeld 2012, Anderson 2007, Da Silva 2004, Brown 2000).
It does not cross the blood-brain barrier (Amir 2011, Gabay 2002, Hofmeyr 1985, Petraglia 1985, Brouwers 1980) as it has no neurological effects, so it would be preferable to metoclopramide for that purpose.
The maternal perception of insufficient milk is one of the main causes of abandoning breastfeeding (Winterfeld 2012, Jones 2011, Zuppa 2010, Amir 2006).
The best galactogogue is effective support and advice during pregnancy and after childbirth to achieve breastfeeding on frequent demand and with correct technique in a mother who retains her self-confidence (Brodribb 2018, Anderson 2013, Mannion 2012, Forinash 2012, Comité 2012, ABM 2011, Jones 2011, Anderson 2007, Amir 2006, Seema 1999).
At a dose of 10 to 20 mg every 8 hours for 2 to 4 weeks, milk production increases, especially in mothers of preterm infants admitted to neonatal units (Taylor 2019, Asztalos 2019, Grzeskowiak 2018, Brodribb 2018, Asztalos 2017, Haase 2016, Rai 2016, Bazzano 2016, Knoppert 2013, Inam 2013, Donovan 2012, Ingram 2012, Osadchy 2012, Campbell 2010, Wan 2008, Da Silva 2001, Petraglia 1985, Hofmeyr 1983), after a Cesarean Section (Jantarasaengaram 2012) and in cases of relactation ( Muresan 2011), lactation induction (Bryant 2006), breast hypoplasia (Duran 2011) and transgender women (Reisman 2018).
Some studies show that it is not effective in all mothers (Wan 2008), that it may cease to be effective by the 4th week of its administration (Asztalos 2017), that there are no significant differences in the increase in milk production with 30 or 60 mg daily (Knoppert 2013), side effects in mothers (abdominal pain, headache and dry mouth) are more frequent at high doses (Wan 2008) and that, despite the increase in milk production, weight gain might not be observed in breastfed infants (Rai 2016) or decreased risk of breastfeeding abandonment (Grzeskowiak 2018).
In order to avoid withdrawal symptoms (Doyle 2018, Papastergiou 2013) it is advisable to carry out a slow progressive withdrawal over several weeks.
Domperidone increases the concentration of calcium in breastmilk without altering the caloric content or that of other components (Campbell 2010).
Domperidone has been associated with an increased risk of severe ventricular arrhythmias in older people (Leelakanok 2016) or with previous cardiac abnormalities (lengthened QT on the ECG) or associated with medications that lengthen the QT (Doggrell 2014), being extraordinarily rare in healthy women of childbearing age (Madjunkov 2017, Smolina 2016). Only one woman with a previous history of arrhythmia presented ventricular arrhythmia among the more than 200,000 treated with domperidone in the postpartum period (Smolina 2016, Grzeskowiak 2018 and 2017).
Do not use as a galactogogue without health checks.
Several medical societies and expert consider the use of this medication to be safe or very probably safe during breastfeeding (Grzeskowiak 2018, Hale 2017 p300, Amir 2011, Zuppa 2010, Marasco 2008, Mahadevan 2006, Lee 1993).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
We do not have alternatives for Domperidone since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM